Description of Invention:
The invention provides composition claims for a scytovirin domain 1 (SD1) antiviral polypeptide, nucleic acids encoding the polypeptide, related fusion proteins and conjugates, isolated cells, vectors, and antibodies that bind to the polypeptide. The polypeptide of this invention has the ability to bind to viral proteins, such as gp41 and gp120 of HIV, and exhibit anti-viral activity against type C and D retroviruses such as HIV-1 and HIV-2, Ebola, SARS, Influenza viruses and others. The invention also provides for methods of use to inhibit viral infections therapeutically and prophylactically as well as methods of inhibiting virus in biological samples or inanimate objects. Thus, further development of the invention may yield novel therapies and methods in the prevention of HIV and other retroviruses, and treatment of chronic infection in patients with resistance to current therapies.
Inventors:
Barry R. O’Keefe et al. (NCI)
Patent Status:
DHHS Reference No. E-180-2005/0 --
U.S. Provisional Application No. 60/684,353 filed 25 May 2005
PCT Application No. PCT/US06/20100 filed 24 May 2006, which published as WO 2006/127822 on 30 Nov 2006
U.S. Patent Application No. 11/914,833 filed 19 Nov 2007
Licensing Status: In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.
For Additional Information Please Contact: Sally Hu PhD MBA
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-5606
Email: hus@mail.nih.gov
Fax: (301) 402-0220
